{"id":40605,"date":"2020-12-26T11:03:32","date_gmt":"2020-12-26T16:03:32","guid":{"rendered":"https:\/\/sciencebusiness.technewslit.com\/?p=40605"},"modified":"2020-12-26T11:03:32","modified_gmt":"2020-12-26T16:03:32","slug":"infographic-late-charge-boosts-biotech-index","status":"publish","type":"post","link":"https:\/\/technewslit.com\/sciencebusiness\/?p=40605","title":{"rendered":"Infographic – Late Charge Boosts Biotech Index"},"content":{"rendered":"
\"Nasdaq<\/a>
Click on image for full-size view (Nasdaq)<\/figcaption><\/figure>\n

26 Dec. 2020. The Nasdaq Biotechnology Index<\/a>, an indicator of investor interest in the industry, rose in December to close up by 26 percent for the year. However, the Biotech Index underperformed the Nasdaq composite index, a financial indicator of the overall technology sector, since the start of 2020.<\/p>\n

Changes in the Nasdaq Biotechnology Index, or NBI, largely mirrored share price movements overall throughout the year. In mid-March 2020, the NBI dropped by nearly a quarter (-24%) from its opening score of 3,878.91 on 2 January, a result the pandemic shock that drove down all share prices. The index then rebounded to 4,297.48 by the end of June, a gain of 45 percent from its mid-March trough.<\/p>\n

We last visited the NBI<\/a> in August, where we found the index maintaining its gains from spring. The Biotech Index continued on cruise control through summer and most of the fall, ranging from 4,000 to 4,500 points. Since the end of November, the NBI rose steadily to reach 4,901.92, its close on 24 December, a gain of 26 percent from the beginning of 2020.<\/p>\n

While that increase is impressive, reflecting share prices of 282 biotech companies trading on the Nasdaq, the Nasdaq Composite Index<\/a>, an indicator of the overall technology-heavy exchange, rose by 41 percent since the start of the year.<\/p>\n

More from Science & Enterprise:<\/p>\n